Kezar Life Sciences, Inc. · NASDAQ:KZR
Kezar Life Sciences — Investor Day (June 2022)
27 slides from Kezar Life Sciences's investor day presentation, Jun 27, 2022
Slide 1: Investor & Analyst Event June 27, 2022
INVESTOR & ANALYST EVENT JUNE 27, 2022 Exhibit 99.1
Slide 2: Forward-Looking Statements and Topline Data Disclaimer
Forward-Looking Statements and Topline Data Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “should,” “expect,” “believe”, “plan” and similar expressions (as well as other words
Slide 3: Agenda
Agenda 4:30 PM – 4:35 PM Welcome, Introductions and Opening Remarks | John Fowler, MBA 4:35 PM – 5:05 PM MISSION Phase 2 Clinical Update | Noreen R. Henig, MD 5:05 PM – 5:10 PM Zetomipzomib Clinical Development Next Steps | Noreen R. Henig, MD 5:10 PM – 5:15 PM Summary and Closing Remarks | John Fow
Slide 4: The Kezar Opportunity: First-in-Class, Small Molecule Therapies for Immune-Mediated Diseases and Cancer
Builds on 10+ years of R&D work in proteasome biology and protein secretion led by Kezar’s scientific co-founders, Chris Kirk & Jack Taunton Deep Expertise in Immunology and Oncology A novel approach to harmonizing the immune system via immunomodulation. Potential to be a pipeline in a drug Zetomipz
Slide 5: Zetomipzomib, a First-in-Class Inhibitor of the Immunoproteasome
Zetomipzomib, a First-in-Class Inhibitor of the Immunoproteasome, Acts Across the Innate and Acquired Immune System Immunoproteasome Inhibition with Zetomipzomib* Zetomipzomib Advantage Decreases pro-inflammatory cytokine production, plasma cell activity and autoantibody production, while increasing
Slide 6: MISSION Phase 2 Topline Data in Lupus Nephritis
MISSION: Topline Data MISSION Phase 2 Study Evaluating Zetomipzomib 60 mg SC QW for 24 Weeks in Lupus Nephritis Abbreviations: SC, subcutaneously; QW, weekly.
Slide 7: MISSION Phase 1b: Safety, Tolerability and Preliminary Efficacy in SLE
MISSION Phase 1b (Complete): Zetomipzomib Demonstrated Safety, Tolerability and Preliminary Efficacy in Patients with SLE with and without LN Treatment with zetomipzomib demonstrated improvements in multiple exploratory measures of disease activity across organ systems including SLEDAI-2K 2 of 2 sub
Slide 8: Topline: Highlights
MISSION Phase 2 Topline: Highlights Zetomipzomib Achieves Clinically Meaningful Overall Renal Response (ORR) in Refractory or Hard-to-Treat LN Patients without Standard Induction Therapy 11/17 (64.7%) patients demonstrated an ORR of ≥50% UPCR reduction following 24 weeks of treatment (primary endpoi
Slide 9: Study Design
MISSION Phase 2: Study Design Open-Label Clinical Study to Evaluate the Efficacy and Safety of Zetomipzomib in Patients with Active Proliferative Lupus Nephritis Adult patients with LN^ (N=21) ^LN patients (Class III or IV +/- Class V) with significant proteinuria (UPCR ≥1.0 measured in 24-hour urin
Slide 10: Study Design Endpoints
MISSION Phase 2: Study Design Endpoints Number of patients with ≥50% reduction in UPCR compared to baseline after 24 weeks of treatment with zetomipzomib Primary Endpoint: Overall Renal Response (ORR) Safety and tolerability of zetomipzomib The number of patients with a complete renal response (CRR)
Slide 11: Topline: Safety Population Key Demographics and Baseline Characteristics
MISSION Phase 2 Topline: Safety Population Key Demographics and Baseline Characteristics Safety Population (N=21) Age, mean (years), range 35.3 (19 - 69) Female, n (%) 19 (90.5) Race, n (%) White Black or African American Asian American Indian/Alaska Native Other Unknown 7 (33.3) 1 (4.8) 1 (4.8) 4 (
Slide 12: Patient Disposition
Received 18 doses Received 12 doses Received 2 doses Received 3 doses MISSION Phase 2 Topline: Patient Disposition* End of Treatment End of Study * Each bar represents one patient in the study. Topline data is subject to audit and verification procedures that could result in material changes in the
Slide 13: Evaluable Population Achieves ORR in 65% and CRR in 35% at Week 25
MISSION Phase 2 Topline: Evaluable Population Zetomipzomib Without Standard Induction Therapy Achieves ORR in 65% and CRR in 35% of Patients at Week 25 Evaluable population (n=17) are patients that did not withdraw before Week 25; Patients received 24 weeks of zetomipzomib; End-of-treatment assessme
Slide 14: CRRs Maintained and Additional ORRs Observed at Week 29
MISSION Phase 2 Topline: Evaluable Population CRRs Are Maintained and Additional ORRs are Observed at Week 29, Post-Treatment with Zetomipzomib Evaluable population (n=17) are patients that did not withdraw before Week 25; Patients received 24 weeks of zetomipzomib; End-of-treatment assessments perf
Slide 15: Evaluable Population Mean UPCR Decreases with 24 Weeks of Treatment
CONFIDENTIAL – DO NOT DISTRIBUTE MISSION Phase 2 Topline: Evaluable Population Mean UPCR Decreases with 24 Weeks of Zetomipzomib Treatment Evaluable population (n=17) are patients that did not withdraw before Week 25; Patients received 24 weeks of zetomipzomib; End-of-treatment assessments performed
Slide 16: Reductions in Proteinuria Achieved with 53% Less Corticosteroids
MISSION Phase 2 Topline: With Zetomipzomib, Reductions in Proteinuria Achieved with 53% Less Corticosteroids Mean Daily Steroid Dose End of Treatment No protocol-mandated steroid taper Other background immunosuppressive doses remained stable 19.2 9.1 8.6 9.9 4 Weeks Post- End of Treatment End of Tre
Slide 17: Evaluable Population Mean eGFR Remains Stable
MISSION Phase 2 Topline: Evaluable Population Mean eGFR Remains Stable End of Treatment 103.9 94.2 101.5 Evaluable population (n=17) are patients that did not withdraw before Week 25; Patients received 24 weeks of zetomipzomib; End-of-treatment assessments performed at Week 25. Stable eGFR defined a
Slide 18: Reduction in Signs and Symptoms of SLE with Zetomipzomib
MISSION Phase 2 Topline: Evaluable Population Reduction in Signs and Symptoms of SLE with Zetomipzomib Treatment Tool Baseline Mean (SD) EOT (Week 25) Mean (SD) SLEDAI-2K 11.1 (4.7) 6.5 (3.1) Physician Global Assessment Score 57.2 (21.7) 23.9 (19.2) Patient Global Assessment Score 23.6 (21.1) 10.7 (
Slide 19: Improvement in Key Serologic Biomarkers at Week 25
MISSION Phase 2 Topline: Evaluable Population Improvement in Key Serologic Biomarkers Observed at Week 25 (EOT) in Patients with Abnormal Levels at Baseline Biomarker Patients with Abnormal Levels at Baseline Patients with Improvement at W25 (EOT) Patients with Normalization at Week 25 (EOT) Anti-ds
Slide 20: Zetomipzomib Continues to Show Favorable Safety and Tolerability Profile
MISSION Phase 2 Topline Data: Safety Population (N=21) Zetomipzomib Continues to Show Favorable Safety and Tolerability Profile Acute protracted migraine (related) Worsening pulmonary arterial hypertension, AKI and UTI (unrelated) Injection site infiltration (related) Asthenia (related) Reticulocyte
Slide 21: Topline: Highlights
MISSION Phase 2 Topline: Highlights Zetomipzomib Achieves Clinically Meaningful Overall Renal Response (ORR) in Refractory or Hard-to-Treat LN Patients without Standard Induction Therapy 11/17 (64.7%) patients demonstrated an ORR of ≥50% UPCR reduction following 24 weeks of treatment (primary endpoi
Slide 22: Zetomipzomib: Clinical Development Next Steps
ZETOMIPZOMIB: Clinical Development Next Steps
Slide 23: Zetomipzomib: Key Attributes
Zetomipzomib, A First-in-Class Inhibitor of the Immunoproteasome: Key Attributes Modulates innate and acquired immune responses without signs of immunosuppression to date Once weekly subcutaneous administration leads to intermittent inhibition of the immunoproteasome with no accumulation observed wi
Slide 24: Zetomipzomib for the Treatment of Lupus Nephritis: Next Steps
Zetomipzomib for the Treatment of Lupus Nephritis: Next Steps 1 2 3 4 Zetomipzomib is Well Positioned for Use as a Chronic Therapy for the Treatment of LN Potential to be used without induction therapy Potential to be steroid-sparing Potential treatment for renal and extra-renal manifestations of SL
Slide 25: Summary and Closing Remarks
Summary and Closing Remarks
Slide 26: Q&A Speakers
Q&A SPEAKERS John Fowler, MBA Chief Executive Officer Noreen R. Henig, MD Chief Medical Officer Christopher J. Kirk, PhD Chief Scientific Officer
Slide 27: Thank You
LIFE SCIENCES THANK YOU